Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Pivotal phase 2 DESTINY-Breast01 trial met primary endpoint, supporting global regulatory submission plan to start in first half of fiscal year 2019 TOKYO and MUNICH and BASKING RIDGE, N.J., May 8, 2019 -- (Healthcare Sales & Marketing Network) -- Daii... Biopharmaceuticals, Oncology Daiichi Sankyo, AstraZeneca, trastuzumab deruxtecan, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 8, 2019 Category: Pharmaceuticals Source Type: news

AstraZeneca-Daiichi breast cancer treatment shows promise in latest study
An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan's Daiichi Sankyo's met its main goal in a mid-stage study, bolstering their position in a highly competitive oncology market. (Source: Reuters: Health)
Source: Reuters: Health - May 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine. (Source: World Pharma News)
Source: World Pharma News - May 8, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca Starts Artificial Intelligence Collaboration to Accelerate Drug Discovery
AstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). (Source: eHealth News EU)
Source: eHealth News EU - May 2, 2019 Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news

AstraZeneca ties up with France's Transgene to develop viral immunotherapies
British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies. (Source: Reuters: Health)
Source: Reuters: Health - May 2, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Tumor cells' drug addiction may be their downfall
(Babraham Institute) Work by researchers at the Babraham Institute in partnership with the global biopharmaceutical company AstraZeneca shows how cancer cells' acquired resistance to anti-cancer drugs proves fatal once the treatment compound is withdrawn. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 2, 2019 Category: Cancer & Oncology Source Type: news

AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery
AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). (Source: World Pharma News)
Source: World Pharma News - April 30, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca cancer drugs drive growth in sales
Group reports robust performance from new oncology treatments and in emerging markets (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 26, 2019 Category: Pharmaceuticals Source Type: news

AstraZeneca research finds lack of good lung cancer information available for patients
Analysis of 885 websites found 65% of sources provided info on differences between non-small cell and small cell lung cancer, but only 29% explained disease staging. Info on treatment, when available, was found to be often either too complex or too high-level and incomplete. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 25, 2019 Category: Consumer Health News Source Type: news

AstraZeneca chief claims vindication five years after Pfizer bid
Some investors and analysts still unconvinced UK company was right to resist approach (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 24, 2019 Category: Pharmaceuticals Source Type: news

Novartis picks Sanjay Murdeshwar of AstraZeneca to lead its India business
Murdeshwar according to his current LinkedIn profile is the Global Vice President, Cardio-Renal business at Astrazeneca. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 22, 2019 Category: Pharmaceuticals Source Type: news

New method to detect off-target effects of CRISPR
(Gladstone Institutes) Since the CRISPR genome editing technology was invented in 2012, it has shown great promise to treat a number of intractable diseases. However, scientists have struggled to identify potential off-target effects in therapeutically relevant cell types, which remains the main barrier to moving therapies to the clinic. Now, a group of scientists at the Gladstone Institutes and the Innovative Genomics Institute (IGI), with collaborators at AstraZeneca, have developed a reliable method to do just that. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 18, 2019 Category: Biology Source Type: news

EC Approves Olaparib for BRCA Breast Cancer EC Approves Olaparib for BRCA Breast Cancer
The European Commission has cleared olaparib (Lynparza, AstraZeneca/MSD) for the treatment of locally advanced or metastatic BRCA1/2 breast cancer.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 16, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Why PhaseBio's stock rose 16 percent Tuesday
PhaseBio's stock closed up 16 percent at $14.61 per share on Tuesday after the company received a key designation from the Food and Drug Administration. The jump came after the FDA granted "breakthrough therapy" status to one of the Malvern company's lead new drug candidate. The experimental product, PB2452, is being developed by PhaseBio as a reversal agent for the antiplatelet drug ticagrelor — marketed by AstraZeneca as Brilinta. Brilinta is most commonly prescribed in heart patients to prevent… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 9, 2019 Category: Health Management Authors: John George Source Type: news

Why PhaseBio's stock rose 16 percent Tuesday
PhaseBio's stock closed up 16 percent at $14.61 per share on Tuesday after the company received a key designation from the Food and Drug Administration. The jump came after the FDA granted "breakthrough therapy" status to one of the Malvern company's lead new drug candidate. The experimental product, PB2452, is being developed by PhaseBio as a reversal agent for the antiplatelet drug ticagrelor — marketed by AstraZeneca as Brilinta. Brilinta is most commonly prescribed in heart patients to prevent… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 9, 2019 Category: Biotechnology Authors: John George Source Type: news

AstraZeneca, Daiichi Sankyo partner on cancer ADC
AstraZeneca has entered into an agreement with Daiichi Sankyo to develop and commercialize trastuzumab deruxtecan (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 5, 2019 Category: Pharmaceuticals Source Type: news

FDA-approved drug effectively treats rare chronic immune disorder
Small NIH clinical trial conducted in partnership with AstraZeneca. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - April 3, 2019 Category: American Health Source Type: news

Novartis subsidiary AveXis buys AstraZeneca site in Colorado
The company plans to rehire all the former AstraZeneca employees to work in the 700,000-square-foot, six-building campus (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 3, 2019 Category: Pharmaceuticals Source Type: news

Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1
AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the MEK 1/2 inhibitor and potential new medicine selumetinib. (Source: World Pharma News)
Source: World Pharma News - April 2, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca: capital remedy
Cancer drug deal will help the pharma group outpace most of its rivals (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 29, 2019 Category: Pharmaceuticals Source Type: news

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche. (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca in $6.9bn cancer deal with Daiichi Sankyo
Pharma companies to share drug development and commercialisation costs as well as profits (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 29, 2019 Category: Pharmaceuticals Source Type: news

AstraZeneca could pay Daiichi Sankyo up to $6.9 billion in cancer drug deal
AstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daiichi's cancer drug trastuzumab deruxtecan that could see the British drugmaker pay as much as $6.9 billion to its Japanese partner. (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca's Imfinzi gets NICE nod for lung cancer
The National Institute for Health and Care Excellence (NICE) said it would cover AstraZeneca's Imfinzi via the Cancer Drugs Fund, for the treatment of certain patients with non-small-cell lung cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 29, 2019 Category: Pharmaceuticals Source Type: news

Forxiga approved in Japan for type-1 diabetes
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). The approval is based on data from the Phase III DEPICT clinical programme and a dedicated trial in Japanese patients (D1695C00001). (Source: World Pharma News)
Source: World Pharma News - March 27, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes
British drugmaker AstraZeneca Plc said on Monday the European Commission approved its diabetes drug Forxiga for use as an oral supplement to insulin in adults with a rare type of the disease. (Source: Reuters: Health)
Source: Reuters: Health - March 25, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Biogen Halts Promising Alzheimer ’s Drug Trials Due to Disappointing Results
Pharmaceutical company Biogen is halting two global phase-three trials testing the once-promising Alzheimer’s drug aducanumab, delivering a late-stage blow to researchers searching for therapies for the incurable degenerative disease. “This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience,” Biogen CEO Michel Vounatsos said in a statement Thursday. “We are incredibly grateful to all the Alzheimer’s disease patients, their families and the investigators who participated in the trials and contributed greatly...
Source: TIME: Health - March 21, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs onetime Source Type: news

US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs. Saracatinib is an inhibitor of src kinase which regulates broad cell functions including cell growth and cell differentiation. (Source: World Pharma News)
Source: World Pharma News - March 18, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca launches push into digital tech
Pharma group hopes push will speed up drug discovery and show value of its medicines (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 17, 2019 Category: Pharmaceuticals Source Type: news

AstraZeneca launches digital tech drive
Pharma group hopes push will speed up drug discovery and show value of its medicines (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 17, 2019 Category: Pharmaceuticals Source Type: news

Seres teams up with AstraZeneca to explore microbiome benefits in cancer treatment
Microbiome-focused biotech Seres Therapeutics is teaming up with drug giant AstraZeneca to explore how the trillions of bacteria in a person ’s gut could help fight cancer. Under the three-year collaboration deal announced Monday, Seres (Nasdaq: MCRB) will evaluate how the bacteria found in the human body, also known as the microbiome, can help predict which patients respond to cancer immuno-therapies. AstraZeneca (NYSE: AZN) may also test Seres’ early-stage drug candidate, SER-401, in combination… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 11, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Automation Is Here To Stay … Hip Hip Hooray!
“Success is the ability to go from one failure to another with no loss of enthusiasm.” So said Winston Churchill, who noted that persistence was not a universal quality amongst his peers. “Never give up.”The problem is, humans are ill-prepared to approach a situation for the hundredth or millionth time without at least facing some dip in performance. The answer is automation, a growing trend in digital investments and one which has recently entered the pharmaceutical industry. Computers can try and try again, with just as much fervor as with the first attempt.Despite this obvious advantage, whe...
Source: EyeForPharma - February 26, 2019 Category: Pharmaceuticals Authors: Catherine Calarco Source Type: news

AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study
British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck& Co met the primary goal in a late-stage study for a rare type of pancreatic cancer. (Source: Reuters: Health)
Source: Reuters: Health - February 26, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca's Lynparza meets main goal of late-stage cancer study
British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck& Co met the primary goal in a late-stage study for pancreatic cancer. (Source: Reuters: Health)
Source: Reuters: Health - February 26, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

THEMIS Top Line: Ticagrelor Cuts Event Risk in Diabetics With CAD THEMIS Top Line: Ticagrelor Cuts Event Risk in Diabetics With CAD
Adding daily ticagrelor (Brilinta/Brilique) to aspirin conferred a significant benefit in the trial with more than 19,000 high-risk diabetics in top-line results announced by AstraZeneca.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 25, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Brilinta ’s Phase III THEMIS trial met primary endpoint in 
patients with established coronary artery disease and type-2 diabetes
The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone. (Source: World Pharma News)
Source: World Pharma News - February 25, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca retires MedImmune brand
The MedImmune name is going away. The Gaithersburg-based research-and-development arm of AstraZeneca PLC (NYSE: AZN) will be folded into its parent as the U.K. company reorganizes its R&D units, the company announced Thursday. The MedImmune brand and logo will disappear, but the Maryland operation will remain as one of AstraZeneca's three R&D sites. Sunsetting the MedImmune brand is “designed to simplify our structure and help make the company more aligned,” a spokeswoman told me in an email.… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 14, 2019 Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news

New drugs help AstraZeneca sales rebound
Pharmaceutical group heralds second quarter of growth as it ends year on a high (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 14, 2019 Category: Pharmaceuticals Source Type: news

Christiana Care to take space at Avenue North complex
Christiana Care Health System  is consolidate a large chunk of its administrative and support services at the new Avenue North campus in North Wilmington. Avenue North is a mixed-use development project of Delle Donne& Associates on the AstraZeneca campus at Route 202 and Powder Mill Road in Fairfax, Del. The project calls for corporate offices, restaurants, retail, residences and a hotel at the site. “We are excited to make this continued commitment to New Castle County as we work to deliver… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 6, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

AstraZeneca's infant respiratory drug prioritised in Europe, U.S.
Britain's AstraZeneca said a potential medicine to prevent respiratory syncytial virus (RSV) in babies and infants had been granted special status by U.S. and European regulators, designed to speed up the development of novel and better drugs. (Source: Reuters: Health)
Source: Reuters: Health - February 5, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for the prevention of lower respiratory tract infection (LRTI) caused by RSV. (Source: World Pharma News)
Source: World Pharma News - February 5, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Forxiga receives positive EU CHMP opinion for the treatment of adults with type-1 diabetes
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxiga (dapagliflozin), after adopting a positive opinion for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D). (Source: World Pharma News)
Source: World Pharma News - February 4, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca, UPMC Health Plan sign risk-sharing deal for heart medicine
AstraZeneca and UPMC Health Plan have entered into what they are calling a "pioneering value-based contract" that covers the Pittsburgh-based health insurer's members who are taking Brilinta. Brilinta is a medication used to lower a patient’s chances of having another heart attack or dying from one in the 12 months following a heart attack. Under the value-based contract, the reimbursement AstraZeneca receives for its medication will be linked to cardiovascular outcomes for UPMC He alth Plan… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 28, 2019 Category: Biotechnology Authors: John George Source Type: news

Pharma stocks fall as Rep. Cummings launches drug pricing investigation
Chairman of the House Oversight Committee Rep. Elijah Cummings (D-MD) launched an investigation today into the drug pricing practices of 12 pharmaceutical companies. A number of companies named in the investigation saw their stock prices fall, including Amgen (NSDQ:AMGN), AbbVie (NYSE:ABBV), AstraZeneca (NYSE:AZN), Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). A hearing is reportedly set for Jan. 29 and will include patients affected by rising drug costs. Get the full story at our sister site, Drug Delivery Business News. The post Pharma stocks fall as Rep. Cummings lau...
Source: Mass Device - January 14, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Featured Pharmaceuticals Wall Street Beat AbbVie Amgen AstraZeneca plc Eli Lilly & Co. Novo Nordisk Sanofi-Aventis Source Type: news

AstraZeneca CMO departs as reorg continues
AstraZeneca's chief medical officer, Sean Bohen is leaving after less than four years at the company, amid the drugmaker's newly announced overhaul. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 14, 2019 Category: Pharmaceuticals Source Type: news

AstraZeneca announces plant closings, layoffs
AstraZeneca will be closing two manufacturing sites in Colorado in order to consolidate its biologics manufacturing network in one large-scale drug substance facility. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 10, 2019 Category: Pharmaceuticals Source Type: news

After MSKCC, Baselga Heads Oncology R & D at AstraZeneca After MSKCC, Baselga Heads Oncology R & D at AstraZeneca
After stirring up heated controversy over failure to disclose industry relationships while at Memorial Sloan Kettering Cancer Center (MSKCC), Baselga now heads to a giant pharma company.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 8, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Allergan joins biotech swarm in Kendall Square with R & D hub
Yet another of biotech's biggest names is moving to Cambridge. Irish pharmaceutical giant Allergan plc announced plans Monday to open a research facility in Kendall Square during the first quarter of 2019. Former AstraZeneca and Pfizer executive and current Allergan Senior Vice President of Research and External Scientific Innovation Don Frail will oversee th e site, according to a news release. The Botox manufacturer did not disclose where the office would be located or how many employees would… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 8, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Top Cancer Doctor, Forced Out Over Ties to Drug Makers, Joins Their Ranks
AstraZeneca has hired Dr. Jos é Baselga, the former chief medical officer at Memorial Sloan Kettering, to lead its cancer research unit. (Source: NYT Health)
Source: NYT Health - January 7, 2019 Category: Consumer Health News Authors: KATIE THOMAS and CHARLES ORNSTEIN Tags: Baselga, Jose AstraZeneca PLC Memorial Sloan-Kettering Cancer Center Drugs (Pharmaceuticals) Conflicts of Interest Source Type: news

AstraZeneca hires former Sloan Kettering specialist to lead oncology R & D unit
AstraZeneca has hired Dr. Jos é Baselga to serve as its head of research and development for oncology. Baselga, 59, was previously chief medical officer at Memorial Sloan Kettering Cancer Center in New York City. He stepped down from that post in September following published reports that he failed at times to disclose certai n financial ties with drug companies in medical journal articles. Baselga also resigned from the Bristol-Myers Squibb Co.'s board of directors that same month. The hiring… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 7, 2019 Category: Biotechnology Authors: John George Source Type: news